In this explorative study, we investigated the idea of biofluid-based staging of AD using measurements of p-tau217, p-tau205 and NTA-tau in CSF and blood, and evaluate whether abnormalities in these biomarkers align with underlying pathological AD hallmarks. Here, MAPT is linked to Alzheimer disease.